Generic (Tepotinib) TEPODX

Inquire / Price
  • Model Number:
    RL3020241030
  • Brand Name:
    TEPODX
  • Origin:
    Generic drug,Laos
  • Small Orders:
    Small batches also available
  • Tags:
Inquire Now Link

Poster
  • Details
  • Description
  • Packaging Size
    60tabs
  • Strength
    225mg
  • Compositon
    Tepotinib
  • Treatment
    Non-small cell lung cancer (NSCLC) with exon 14 skipping
  • Form
    Tablet
  • Brand
    TEPODX
  • Quantity Unit
    225mg*60tabs
  • Manufacturer
    BIGBEAR Pharma,Laos PDR

About Tepotinib

Tepotinib is a kinase inhibitor directed against MET, including variants with exon 14 skipping - it inhibits MET phosphorylation and subsequent downstream signaling pathways in order to inhibit tumor cell proliferation, anchorage-independent growth, and migration of MET-dependent tumor cells.

Non–Small Cell Lung Cancer

Indicated for metastatic non–small cell lung cancer (NSCLC) in adults harboring mesenchymal-epithelial transition (MET) exon 14 (ex14) skipping alterations

450 mg PO qDay

Continue until disease progression or unacceptable toxicity

Dosage Modifications

Recommended dose reduction to manage adverse reactions: 225 mg PO qDay

Permanently discontinue if unable to tolerate 225 mg PO qDay

Interstitial lung disease (ILD)/ pneumonitis

  • Suspected ILD (any grade): Withhold
  • Confirmed ILD: Permanently discontinue

Increased AST/ALT and/or total bilirubin

  • Grade 3 increased AST/ALT without increased total bilirubin
    • Withhold until recovery to baseline ALT/AST
    • If recovered to baseline ≤7 days, resume at same dose; otherwise, resume at a reduced dose
  • Grade 3 increased total bilirubin without concurrent increased AST/ALT
    • Withhold until recovery to baseline total bilirubin
    • If recovered to baseline ≤7 days, resume at reduced dose; otherwise, permanently discontinue
  • Permanently discontinue
    • Grade 4 increased ALT/AST without increased total bilirubin
    • ALT/AST >3x ULN with total bilirubin >2x ULN without cholestasis or hemolysis
    • Grade 4 increased total bilirubin without concurrent increased AST/ALT

Other adverse reactions

  • Grade 2: Maintain dose; if intolerable, consider withholding until resolved, then resume at reduced dose
  • Grade 3: Withhold until resolved, then resume at reduced dose
  • Grade 4: Permanently discontinue

Renal impairment

  • Mild-to-moderate (CrCl 30-89 mL/min): No dosage adjustment necessary
  • Severe (CrCl <30 mL/min): Recommended dose not established

Hepatic impairment

  • Mild-to-moderate (Child-Pugh Class A or B): No dosage adjustment necessary
  • Severe (Child-Pugh Class C): Pharmacokinetics and safety not studied

Link

Poster

Top